• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cascade testing for the identification of carriers of cystic fibrosis.

作者信息

Holloway S, Brock D J

机构信息

Human Genetics Unit, University of Edinburgh, Western General Hospital, United Kingdom.

出版信息

J Med Screen. 1994 Jul;1(3):159-64. doi: 10.1177/096914139400100305.

DOI:10.1177/096914139400100305
PMID:8790509
Abstract

It has been suggested that cascade testing, in which relatives of a person affected with cystic fibrosis (CF) are tested for carrier status, is preferable to screening individuals in the general population. This idea was examined by calculating the number of relatives requiring testing, assuming that it is necessary to identify all those of reproductive age no more distantly related to the proband than second cousins. Two hypothetical programmes were used, in each of which only blood relatives of an affected proband were tested and subsequent analysis applied to relatives of those with a positive result. If started in the grandparental generation, cascade testing of about 28 relatives for each proband would detect 86.4% of carriers in the family. If only carried out for the parental generation and their descendants, testing of about 35 relatives for each proband would detect 92.1% of carriers in the family. If cascade testing were restricted to the second cousin level, however, these programmes would only detect between 8 and 24% of all carrier couples. This contrasts with the 50% detection rate that has already been demonstrated for antenatal CF screening.

摘要

相似文献

1
Cascade testing for the identification of carriers of cystic fibrosis.
J Med Screen. 1994 Jul;1(3):159-64. doi: 10.1177/096914139400100305.
2
Active cascade testing for carriers of cystic fibrosis gene.对囊性纤维化基因携带者进行活性级联检测。
BMJ. 1994 Jun 4;308(6942):1462-7. doi: 10.1136/bmj.308.6942.1462.
3
Cascade carrier-testing in cystic fibrosis.囊性纤维化的级联携带者检测
Paediatr Respir Rev. 2003 Dec;4(4):293-8.
4
Screening for carriers of cystic fibrosis--a general practitioner's perspective.囊性纤维化携带者的筛查——全科医生视角
BMJ. 1993 Oct 2;307(6908):849-52. doi: 10.1136/bmj.307.6908.849.
5
Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis.对囊性纤维化携带者进行全社区筛查可替代新生儿筛查来诊断囊性纤维化。
J Paediatr Child Health. 2007 Nov;43(11):721-3. doi: 10.1111/j.1440-1754.2007.01224.x.
6
Human Genetics Society of Australasia position statement: population-based carrier screening for cystic fibrosis.澳大利亚人类遗传学会立场声明:基于人群的囊性纤维化携带者筛查
Twin Res Hum Genet. 2014 Dec;17(6):578-83. doi: 10.1017/thg.2014.65.
7
A 10-year large-scale cystic fibrosis carrier screening in the Italian population.意大利人群中一项长达 10 年的大型囊性纤维化携带者筛查。
J Cyst Fibros. 2010 Jan;9(1):29-35. doi: 10.1016/j.jcf.2009.10.003. Epub 2009 Nov 7.
8
Effect of family history on disclosure patterns of cystic fibrosis carrier status.家族史对囊性纤维化携带者状态披露模式的影响。
Am J Med Genet C Semin Med Genet. 2003 May 15;119C(1):70-7. doi: 10.1002/ajmg.c.10008.
9
Identification of carriers by screening for delta F508 deletion in a multi-generation cystic fibrosis family.
Genet Couns. 1990;1(3-4):211-7.
10
Association between carrier screening and incidence of cystic fibrosis.携带者筛查与囊性纤维化发病率的关系。
JAMA. 2009 Dec 16;302(23):2573-9. doi: 10.1001/jama.2009.1758.

引用本文的文献

1
An Examination of the Ethical and Legal Limits in Implementing "Traceback Testing" for Deceased Patients.对实施已故患者“溯源检测”的伦理和法律限制的考察。
J Law Med Ethics. 2022;50(4):818-832. doi: 10.1017/jme.2023.23.
2
Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.基于诊断后癌症基因检测的级联分析:一种替代基于人群的筛查方法。
J Clin Oncol. 2020 May 1;38(13):1398-1408. doi: 10.1200/JCO.19.02010. Epub 2020 Jan 10.
3
Disclosing to parents newborn carrier status identified by routine blood spot screening.
向父母披露通过常规血斑筛查确定的新生儿携带者状态。
Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD003859. doi: 10.1002/14651858.CD003859.pub2.
4
Estimating the efficacy and efficiency of cascade genetic screening.评估级联基因筛查的有效性和效率。
Am J Hum Genet. 2001 Aug;69(2):361-70. doi: 10.1086/321973. Epub 2001 Jun 26.
5
Costs, effects, and savings of screening for cystic fibrosis gene carriers.囊性纤维化基因携带者筛查的成本、效果及节省情况。
J Epidemiol Community Health. 1998 Jul;52(7):459-67. doi: 10.1136/jech.52.7.459.
6
Cystic fibrosis heterozygote screening in 5,161 pregnant women.对5161名孕妇进行囊性纤维化杂合子筛查。
Am J Hum Genet. 1996 Apr;58(4):823-35.
7
Carrier screening in the community.社区中的携带者筛查。
J Inherit Metab Dis. 1995;18(4):525-32. doi: 10.1007/BF00710064.